RecruitingPhase 1NCT06644755
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Studying Myxoid/round cell liposarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Daiichi Sankyo
- Intervention
- DS-2243a(drug)
- Enrollment
- 150 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (7)
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Sarah Cannon Research Institute, Nashville, Tennessee, United States
- UZ Leuven Europe Leuven, Leuven, Belgium
- Centre Leon Berard, Lyon, France
- Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL), Amsterdam, Netherlands
- Seoul National University Hospital, Seoul, South Korea
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06644755 on ClinicalTrials.govOther trials for Myxoid/round cell liposarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06414434BTX-A51 in Patients With Liposarcoma or CIC-rearranged SarcomaMichael Wagner, MD
- RECRUITINGPHASE1NCT06083883Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1M.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE1NCT05492682START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of CancerValo Therapeutics Oy
- ACTIVE NOT RECRUITINGPHASE2NCT04044768Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell LiposarcomaUSWM CT, LLC